XERIS BIOPHARMA HOLDINGS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period
XERIS BIOPHARMA HOLDINGS, INC. (XERS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period of 194.68 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod · last filed 2026-08-06
- XERIS BIOPHARMA HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2026-06-30 was 125.94K shares, a 170.84% increase year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2026-03-31 was 68.74K shares, a 165.25% increase year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-12-31 was 325.81K shares, a 266.32% increase year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-09-30 was 132.15K shares, a 21707.26% increase year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2025 was 530.38K shares, a 355.22% increase from fiscal 2024.
- XERIS BIOPHARMA HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2024 was 116.51K shares, a 75.37% decline from fiscal 2023.
- XERIS BIOPHARMA HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2023 was 473.05K shares, a 72.79% decline from fiscal 2022.
- XERIS BIOPHARMA HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2022 was 1.74M shares, a 659.23% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 125.94K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | 194.68K shares 10-Q · filed 2026-08-06 | 520.49K shares derived: sum of 3 quarters · filed 2026-08-06 | 652.64K shares derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 68.74K shares 10-Q · filed 2026-05-07 | 394.55K shares derived: sum of 2 quarters · filed 2026-05-07 | 526.70K shares derived: sum of 3 quarters · filed 2026-05-07 | 573.20K shares derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | 325.81K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | 457.96K shares derived: sum of 2 quarters · filed 2026-03-02 | 504.46K shares derived: sum of 3 quarters · filed 2026-03-02 | 530.38K shares 10-K · filed 2026-03-02 |
| 2025-09-30 | 132.15K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 178.65K shares derived: sum of 2 quarters · filed 2025-11-06 | 204.57K shares 10-Q · filed 2025-11-06 | 293.51K shares derived: sum of 4 quarters · filed 2025-11-06 |
| 2025-06-30 | 46.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | 72.41K shares 10-Q · filed 2025-08-07 | 161.36K shares derived: sum of 3 quarters · filed 2025-08-07 | 161.96K shares derived: sum of 4 quarters · filed 2025-08-07 |
| 2025-03-31 | 25.91K shares 10-Q · filed 2025-05-08 | 114.86K shares derived: sum of 2 quarters · filed 2025-05-08 | 115.46K shares derived: sum of 3 quarters · filed 2025-05-08 | 115.87K shares derived: sum of 4 quarters · filed 2025-05-08 |
| 2024-12-31 | 88.94K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | 89.55K shares derived: sum of 2 quarters · filed 2025-03-06 | 89.95K shares derived: sum of 3 quarters · filed 2025-03-06 | 116.51K shares 10-K · filed 2025-03-06 |
| 2024-09-30 | 606.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | 1.01K shares derived: sum of 2 quarters · filed 2024-11-08 | 27.57K shares 10-Q · filed 2024-11-08 | 74.59K shares derived: sum of 4 quarters · filed 2025-03-06 |
| 2024-06-30 | 406.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 26.96K shares 10-Q · filed 2024-08-08 | 73.99K shares derived: sum of 3 quarters · filed 2025-03-06 | 133.58K shares derived: sum of 4 quarters · filed 2025-03-06 |
| 2024-03-31 | 26.56K shares 10-Q · filed 2024-05-09 | 73.58K shares derived: sum of 2 quarters · filed 2025-03-06 | 133.17K shares derived: sum of 3 quarters · filed 2025-03-06 | 369.24K shares derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-12-31 | 47.03K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | 106.61K shares derived: sum of 2 quarters · filed 2025-03-06 | 342.68K shares derived: sum of 3 quarters · filed 2025-03-06 | 473.05K shares 10-K · filed 2025-03-06 |
| 2023-09-30 | 59.59K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 295.65K shares derived: sum of 2 quarters · filed 2023-11-09 | 426.02K shares 10-Q · filed 2023-11-09 | 531.59K shares derived: sum of 4 quarters · filed 2024-03-06 |
| 2023-06-30 | 236.07K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | 366.43K shares 10-Q · filed 2023-08-08 | 472.00K shares derived: sum of 3 quarters · filed 2024-03-06 | 640.39K shares derived: sum of 4 quarters · filed 2024-03-06 |
| 2023-03-31 | 130.37K shares 10-Q · filed 2023-05-09 | 235.94K shares derived: sum of 2 quarters · filed 2024-03-06 | 404.32K shares derived: sum of 3 quarters · filed 2024-03-06 | 991.21K shares derived: sum of 4 quarters · filed 2024-03-06 |
| 2022-12-31 | 105.57K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | 273.95K shares derived: sum of 2 quarters · filed 2024-03-06 | 860.84K shares derived: sum of 3 quarters · filed 2024-03-06 | 1.74M shares 10-K · filed 2024-03-06 |
| 2022-09-30 | 168.38K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | 755.27K shares derived: sum of 2 quarters · filed 2022-11-09 | 1.63M shares 10-Q · filed 2022-11-09 | |
| 2022-06-30 | 586.89K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | 1.46M shares 10-Q · filed 2022-08-10 | ||
| 2022-03-31 | 877.42K shares 10-Q · filed 2022-05-11 | |||
| 2021-12-31 | 228.95K shares 10-K · filed 2022-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |